Goldilocks Therapeutics

Goldilocks Therapeutics is a private U.S. biotech company developing kidney-targeted therapies for acute and chronic renal diseases. Its core technology is a proprietary mesoscale nanoparticle platform designed to deliver therapeutic payloads selectively to the renal tubule epithelium, with the goal of improving kidney exposure while limiting off-target toxicity. Publicly described pipeline efforts have focused on acute kidney injury and polycystic kidney disease, including nanoparticle delivery of agents such as Toll-like receptor 9 antagonists and rapamycin/sirolimus. The company appears to remain at the preclinical stage and has been associated with founders and scientific leadership from Memorial Sloan Kettering and nephrology research collaborators. Goldilocks Therapeutics is headquartered in Bedford, New York and operates as a private, active company.